The Xenomycin family of compounds has a broad range of potential applications as antimicrobial and anti-fungal agents. Xenomycins target basic microbial transcription and replication by binding the DNA of pathogens in a way (intercalating), which does not affect similar functions in mammalian cells.

Preclinical studies demonstrated efficacy of these compounds against parasites causing candidiasis, malaria, trypanosomiasis, and Chagas disease, including those with demonstrated resistance to other drugs.

Our majority owned subsidiary, Panacela holds worldwide development and commercialization rights to Revercom.

You are now leaving this website. If you would like to continue, click Continue.